Osei-Kwasi M, Afari E A, Mimura K, Obeng-Ansah I, Ampofo W K, Nkrumah F K
Noguchi Memorial Institute for Medical Research, University of Ghana, Legon.
Bull World Health Organ. 1995;73(1):41-6.
To evaluate the efficacy of the schedule currently recommended for immunization with trivalent oral poliovirus vaccine (TOPV) (i.e., at birth, 6 weeks, 10 weeks, and 14 weeks after birth), we randomly assigned 452 infants into test (231 infants) and control (221 infants) groups. The test group received TOPV as currently recommended, and the dose at birth was omitted for the control group. At 10, 14, and 18 weeks of age, the levels of poliovirus neutralizing antibodies as well as seroconversion rates were consistently higher for the test group than for the control group. The final seroconversion rates against poliovirus types 1, 2, and 3 were 83.5%, 91% and 83%, respectively, for the test group and 75%, 83.2%, and 79.1%, respectively, for the control group. The TOPV immunization schedule starting at birth therefore produced better results. Seroconversion rates as well as antibody levels were highest in infants with low maternal antibodies.
为评估目前推荐的三价口服脊髓灰质炎疫苗（TOPV）免疫程序（即出生时、出生后6周、10周和14周）的效果，我们将452名婴儿随机分为试验组（231名婴儿）和对照组（221名婴儿）。试验组按照目前推荐的程序接种TOPV，对照组则省略出生时的剂量。在10周、14周和18周龄时，试验组的脊髓灰质炎病毒中和抗体水平及血清转化率始终高于对照组。试验组针对脊髓灰质炎1型、2型和3型的最终血清转化率分别为83.5%、91%和83%，对照组分别为75%、83.2%和79.1%。因此，从出生开始的TOPV免疫程序产生了更好的效果。母体抗体水平低的婴儿血清转化率和抗体水平最高。
